AI Derived Therapeutic Development for the Treatment of Opioid Use Disorder
February 26, 2024
About GATC
GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating novel intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.
Contact Us
Similar News
Islet Transplantation using one’s own Differentiated stem cells: A Review and Potential Applications
Read more
Novel, Artificial Intelligence-based Approaches to the Mitigation and Treatment of Post-Traumatic Stress Disorder (PTSD) in Affected Populations
Read more